Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III TrialKarim Fizazi, Stéphane Culine, Gwénaël Le Teuff et al.|Journal of Clinical Oncology|2024Cited by 18
Docetaxel-estramustine in high-risk localized prostate cancer: First results of the French Genitourinary Tumor Group phase III trial (GETUG 12).Karim Fizazi, Stéphane Culine, Jean François Berdah et al.|Journal of Clinical Oncology|2011Cited by 9
Phase II trial of sunitinib in renal cell cancer with untreated brain metastases.Christine Chevreau, Alain Ravaud, Bernard Escudier et al.|Journal of Clinical Oncology|2011Cited by 7
Phase III study of addition of docetaxel (D) to hormonal therapy (HT) versus HT alone in nonmetastatic high-risk prostate cancer (PC) patients (pts): Final results on PSA progression-free survivalStéphane Oudard, Stéphane Culine, I. Latorzeff et al.|Journal of Clinical Oncology|2011Cited by 3
Nonmetastatic, high-risk prostate cancer patients with biochemical relapse after local treatment: A prospective, randomized phase III study comparing hormonal therapy ± docetaxel—An analysis of final safety results.Stéphane Oudard, Stéphane Culine, I. Latorzeff et al.|Journal of Clinical Oncology|2010Cited by 1